mortality/aging
• mice fail to survive beyond 72 hours after treatment with an LPS dose that is sub-lethal to wild-type mice
|
immune system
• LPS-treated mice exhibit a 4-fold increase in neutrophil influx into the peritoneal cavity with a 2-fold increase in the neutrophil-attractant CXCL11 compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit a 3.5- and 2-fold (at 3 and 6 hours) increase in serum IL6 levels compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit a 3- and 34-fold (at 3 and 6 hours) increase in IL6 at the site of injection compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit an increase in serum IL6 (3.5-fold at 3 hours, 2-fold at 6 hours), IL6 secretion into the peritoneal cavity (3-fold at 3 hours, 32-fold at 6 hours), neutrophil infiltration into the peritoneal cavity, and increased mortality compared with similarly treated wild-type mice
• however, LPS-induced IL10 production is normal
|
homeostasis/metabolism
• LPS-treated mice exhibit a 3.5- and 2-fold (at 3 and 6 hours) increase in serum IL6 levels compared with similarly treated wild-type mice
|
• mice fail to survive beyond 72 hours after treatment with an LPS dose that is sub-lethal to wild-type mice
|
hematopoietic system
• LPS-treated mice exhibit a 4-fold increase in neutrophil influx into the peritoneal cavity with a 2-fold increase in the neutrophil-attractant CXCL11 compared with similarly treated wild-type mice
|